Cancer discovery research generates the knowledge, information, and instruments that drive progress in preventing, diagnosing, and treating the disease, but this work often spans years before any commercial possibility emerges, according to a new report published by the Milken Institute on November 11, 2026. The report warns that current funding cycles don't always deliver the continuity and adaptability this research requires, placing research teams, shared facilities, and promising scientific findings at risk. To address these gaps, the authors propose four new financing and partnership structures designed to keep discovery work moving forward.
The first model calls for establishing a precompetitive discovery consortium that would combine multiyear funding, datasets, and scientific know-how around common research questions, with clear rules governing access, publication rights, and attribution to let organizations work together before they compete on individual products. A second approach—dubbed a philanthropic carry fund—would invite investment managers to commit a portion of their fund profits to an independent pool for discovery grants, with awards determined through scientific peer review and no expectation of financial returns from the research itself. The third option is a milestone-based discovery fund that would support work beyond the scope of individual grants through three separate pathways: continuing productive research, preparing data and tools for broader distribution, and getting selected discoveries ready for commercial translation, all guided by independent scientific oversight. The fourth mechanism is a cancer discovery bond, which would bring future committed funding into the present by borrowing against binding multiyear philanthropic commitments, with donor payments covering both repayment and financing costs regardless of research outcomes.
The report presents these four models as practical alternatives to fill the financing void that occurs when early-stage cancer research has moved past basic science but hasn't yet attracted private investment. The authors emphasize that agreed-upon frameworks for data sharing, intellectual property, and credit assignment would be essential to making collaborative structures work. Each model is designed to operate independently of immediate commercial prospects, recognizing that fundamental discoveries often need sustained support before their therapeutic value becomes clear.
The gap these models aim to close matters because cancer cases worldwide are projected to hit 30 million per year by 2050, creating mounting pressure on research systems to accelerate the pace from laboratory insight to patient benefit. The report argues that without more flexible, longer-term financing structures, promising lines of inquiry risk abandonment at precisely the moment when they're most scientifically productive but least commercially attractive. The proposed models would let funders pool risk, smooth out the boom-and-bust cycles of grant renewals, and keep talented research teams intact through the extended timelines that discovery work demands. By decoupling discovery funding from near-term product development, the authors contend, these approaches could unlock scientific breakthroughs that traditional funding mechanisms leave stranded between public grants and private capital.